Find, compare & contact
Dorzolamid (Dorzolamide) API Manufacturers & Suppliers

Looking for Dorzolamide API 120279-96-1?

Description:

Here you will find a list of producers, manufacturers and distributors of Dorzolamide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Dorzolamide 

Synonyms:

Dorzolamid , Dorzolamida , Dorzolamide , Dorzolamidum , Dorzolamide hydrochloride  

Cas Number:

120279-96-1 

DrugBank number:

DB00869 

Unique Ingredient Identifier:

9JDX055TW1

Dorzolamide is a type of Carbonic anhydrase(II) inhibitors

Carbonic anhydrase (CA) inhibitors are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that specifically target the enzyme carbonic anhydrase II (CAII). CAII is a zinc metalloenzyme that plays a crucial role in the regulation of acid-base balance and fluid secretion in various tissues and organs.

These inhibitors are designed to selectively bind to CAII and inhibit its enzymatic activity. By doing so, they disrupt the conversion of carbon dioxide (CO2) to bicarbonate ions (HCO3-) and protons (H+), which is a fundamental process in many physiological functions.

The inhibition of CAII has been found to be useful in the treatment of several medical conditions. One of the most common applications is in the management of glaucoma, a condition characterized by increased intraocular pressure. By inhibiting CAII in the ciliary body of the eye, these inhibitors reduce the production of aqueous humor, thus lowering the intraocular pressure.

In addition to glaucoma, CAII inhibitors have shown promise in the treatment of other disorders such as epilepsy, edema, and certain types of cancer. Their ability to modulate the pH and ion balance in tissues makes them potential therapeutic agents in a wide range of conditions.

The development of CAII inhibitors involves extensive structure-activity relationship studies and optimization of chemical properties to enhance potency, selectivity, and pharmacokinetic properties. Various structural classes of CAII inhibitors have been synthesized and tested, providing a rich pool of potential drug candidates.

In conclusion, carbonic anhydrase II inhibitors are a valuable subcategory of pharmaceutical APIs that hold promise for the treatment of various medical conditions. Continued research and development in this field may lead to the discovery of novel and effective therapies in the future.

Dorzolamide (Carbonic anhydrase(II) inhibitors), classified under Anticoagulants

Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.

There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.

Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.

While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.

In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.

• SETV Global from India, product country of origin India
• Shandong Octagon Chemicals Limited from China, product country of origin China
• AXXO GmbH from Germany, product country of origin European Union
• TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
• Teva API from Israel, product country of origin Unknown
• Indoco Remedies from India, product country of origin India
• PCAS from France, product country of origin Unknown
• Quimdis from France, product country of origin Unknown
• Hetero Drugs from India, product country of origin India
• Micro Labs from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.